FC
EW icon

Fairpointe Capital’s Edwards Lifesciences EW Stock Holding History

Fairpointe Capital’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-4,193,820
Closed -$71.4M – 81
2014
Q3 		$71.4M Sell
4,193,820
-5,507,268
-57% -$86.9M 0.95% 46
2014
Q2 		$139M Sell
9,701,088
-9,259,098
-49% -$126M 1.85% 31
2014
Q1 		$234M Buy
18,960,186
+609,396
+3% +$7.03M 3.19% 3
2013
Q4 		$201M Buy
18,350,790
+16,485,390
+884% +$186M 2.93% 7
2013
Q3 		$21.6M Buy
+1,865,400
New +$21.8M 0.36% 53

Other funds holding EW

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Fairpointe Capital's EW Position: Q4 2014 in Review

Fairpointe Capital sold out of Edwards Lifesciences (EW) in Q4 2014, closing a stake of 4,193,820 shares — an estimated $71.4M sold.

Fairpointe Capital first reported a position in EW in Q3 2013 and held it in 5 quarters. The position peaked at $234M in Q1 2014. 556 funds tracked by Wall St. Rank hold EW as of Q4 2014.

  • Fairpointe Capital reported no remaining Edwards Lifesciences position as of Q4 2014 after selling out during the quarter.
  • Fairpointe Capital sold 4,193,820 Edwards Lifesciences shares in Q4 2014, an estimated $71.4M.
  • Fairpointe Capital first reported a position in Edwards Lifesciences in Q3 2013 and held it in 5 quarters.
  • Fairpointe Capital's Edwards Lifesciences position peaked at $234M in Q1 2014.
  • 556 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2014.

Based on Fairpointe Capital's 13F filing for Q4 2014, filed 11 Feb 2015.